Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

被引：2

作者：

Mateos, Maria-Victoria ^{[1
]}

Usmani, Saad Z. ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Vorobyev, Vladimir I. ^{[4
]}

Spicka, Ivan ^{[5
]}

Hungria, Vania T. M. ^{[6
]}

Korenkova, Sibirina ^{[7
]}

Bahlis, Nizar ^{[8
]}

Flogegard, Max ^{[9
]}

Blade, Joan ^{[10
]}

Moreau, Philippe ^{[14
]}

Kaiser, Martin F. ^{[11
]}

Iida, Shinsuke ^{[12
]}

Laubach, Jacob P. ^{[13
]}

Masterson, Tara ^{[15
]}

Lantz, Kristen Anne ^{[15
]}

O'Rourke, Lisa ^{[15
]}

Qin, Xiang ^{[16
]}

Parasrampuria, Dolly A. ^{[15
]}

Heuck, Christoph ^{[15
]}

Qi, Ming ^{[15
]}

Nahi, Hareth ^{[17
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[4] SP Botkin City Clin Hosp, Moscow, Russia

[5] Gen Fac Hosp, Prague, Czech Republic

[6] Santa Casa Med Sch, Sao Paulo, Brazil

[7] Kiev Ctr Bone Marrow Transplantat, Kiev, Ukraine

[8] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[9] Falun Gen Hosp, Dept Internal Med, Falun, Sweden

[10] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[11] Inst Canc Res, Div Mol Pathol, Sutton, Surrey, England

[12] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[13] Harvard Med Sch, Dana Farber Canc Inst, Dept Hematol & Oncol, Boston, MA 02115 USA

[14] Univ Hosp Nantes, Nantes, France

[15] Janssen Res & Dev LLC, Spring House, PA USA

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Karolinska Inst, Karolinska Univ Hosp, Div Hematol, Dept Med, Huddinge, Sweden

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122501

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1906

引用

页数：5

共 50 条

[31] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Grosicki, Sebastian
Crafoord, Jacob
Koh, Youngil
White, Darrel
Mellqvist, Ulf-Henrik
Leip, Eric
Kudla, Arthur
Finn, Gregory
Pruchniewski, Lukasz
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Palumbo, Antonio
White, Darrell
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Moreau, Philippe
Mateos, Maria-Victoria
Magen-Nativ, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Taniwaki, Masafumi
Roellig, Christoph
Singhal, Anil K.
Katz, Jessica
Bleickardt, Eric W.
Poulart, Valerie
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[33] CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Costa, Luciano
Mateos Manteca, Maria-Victoria
Voorhees, Peter M.
Iida, Shinsuke
Cole, Craig
Quach, Hang
Pothacamury, Rajvineeth
Bueno, Orlando
Lee, Shane
Rosenberg, Tanya
Talati, Chetasi
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S47 - S48
[34] This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
Dimopoulos, M. A.
Oriol, A.
Nahi, H.
Miguel, J. S.
Bahlis, N. J.
Rabin, N.
Orlowski, R.
Komarnicki, M.
Suzuki, K.
Plesner, T.
Samoilova, O. S.
Yoon, S. S.
Yehuda, D. B.
Richardson, P. G.
Goldschmidt, H.
Reece, D.
Khokhar, N.
O'Rourke, L.
Chiu, C.
Qin, X.
Guckert, M.
Ahmadi, T.
Moreau, P.
HAEMATOLOGICA, 2016, 101 : 342 - 342
[35] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Nizar J. Bahlis
Meletios A. Dimopoulos
Darrell J. White
Lotfi Benboubker
Gordon Cook
Merav Leiba
P. Joy Ho
Kihyun Kim
Naoki Takezako
Philippe Moreau
Jonathan L. Kaufman
Maria Krevvata
Christopher Chiu
Xiang Qin
Linda Okonkwo
Sonali Trivedi
Jon Ukropec
Ming Qi
Jesus San-Miguel
Leukemia, 2020, 34 : 1875 - 1884
[36] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Bahlis, Nizar J.
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Krevvata, Maria
Chiu, Christopher
Qin, Xiang
Okonkwo, Linda
Trivedi, Sonali
Ukropec, Jon
Qi, Ming
San-Miguel, Jesus
LEUKEMIA, 2020, 34 (07) : 1875 - 1884
[37] Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio
Chanan-Khan, Asher Alban Akmal
Weisel, Katja
Nooka, Ajay K.
Masszi, Tamas
Beksac, Meral
Spicka, Ivan
Hungria, Vania T. M.
Mateos, Maria-Victoria
Mark, Tomer Martin
Qi, Ming
Schecter, Jordan Mark
Amin, Himal
Qin, Xiang
Deraedt, William
Ahmadi, Tahamtan
Spencer, Andrew
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
[38] Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Nahi, Hareth
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Bandyopadhyay, Nibedita
Hellemans, Peter
Tromp, Brenda
Nnane, Ivo
Zemlickis, Donna
Farnsworth, Andrew
Chari, Ajai
BLOOD, 2021, 138
[39] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos, Meletios
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10245): : 186 - 197
[40] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178

← 1 2 3 4 5 →